SB290157 trifluoroacetate is primarily utilized in research settings as a selective and potent antagonist for the C3a receptor (C3aR). It is widely employed in immunological and inflammatory studies to investigate the role of the C3a-C3aR signaling pathway in various disease models. Researchers use it to block C3aR activation, helping to elucidate the receptor's involvement in conditions such as asthma, sepsis, rheumatoid arthritis, and other inflammatory disorders. Its application extends to in vitro and in vivo experiments, where it aids in understanding the mechanisms of immune response modulation and potential therapeutic targets. Additionally, it serves as a valuable tool in drug discovery and development processes aimed at designing inhibitors for C3aR-related pathologies.